Allergan Inc. said that it will file a lawsuit against the federal health authorities in an effort to end US restrictions on its offering information on off-label applications of Botox.

The company said that it is “seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of Botox (onabotulinumtoxinA) for certain ‘off-label’ therapeutic uses…”

The US Food and Drug Administration has only approved Botox for selected applications. However, doctors often prescribe the anti-wrinkle drug for other purposes they see fit.
Allergan claims that the current policy violates its First Amendment right.

Source: MarketWatch